We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Blood Test Approach Helps Identify or Rule-Out Heart Attack

By LabMedica International staff writers
Posted on 13 Jun 2016
Two new studies have suggested that modified algorithms using the high-sensitivity cardiac troponin I (hs-CTrop-I) assay could help more quickly identify or exclude the diagnosis of a heart attack for patients reporting to an emergency department (ED) with suspected cardiac chest pain.

Current American Heart Association (AHA) guidelines recommend serial measurements of CT at presentation and 3-6 hours after symptom onset. More...
As a result, most patients require prolonged assessment prior to safe discharge. This diagnostic approach leads to a large number of costly, potentially avoidable hospital admissions. Strategies that could safely identify a large proportion of patients suitable for discharge after a single sample of blood is taken on ED arrival would have major benefits to health care systems.

In one study, Edward Carlton, PhD, North Bristol National Health Service Trust (Bristol, England), and colleagues determined the diagnostic performance of low concentrations of hs-CTrop-I in patients with suspected cardiac chest pain and an electrocardiogram showing no ischemia as an indicator of acute myocardial infarction (AMI; heart attack). The researchers analyzed 5 international (Australia, New Zealand, and England) observational cohort studies with outcome assessment and 30-day follow-up. A total of 3,155 patients presenting with symptoms suggestive of cardiac ischemia were included in the analysis. Eligible patients had a nonischemic electrocardiogram determined and hs-CTrop-I measured at presentation. The lower limit of detection (1.2 ng/L) as well as rounded cutoff concentrations for a hs-CTrop-I assay were used in the analysis.

AMI developed in 291 individuals (9.2%). hs-CTrop-I concentrations that were below the limit of detection identified 19% of patients as being potentially suitable for immediate discharge, with a high diagnostic performance in excluding AMI.

“To place these results in the context of absolute numbers of presenting patients, a number-needed-to-diagnose approach shows that, for the 1.2 ng/L cutoff level, for every 10,630 patients assessed: 1,990 would be correctly reassured that they are not having an AMI, 10 would be falsely reassured, and 8,630 would undergo further investigation, of whom 990 would ultimately receive a diagnosis of AMI. We also demonstrate that cutoff values above the lower limit of detection may not have the required diagnostic performance for clinical implementation,” the authors wrote.

In the second study, Dirk Westermann, MD, University Hospital – Medical Center Hamburg-Eppendorf (Hamburg, Germany) and colleagues aimed to develop an algorithm for accurate and rapid exclusion and diagnosis of AMI after 1 hour. Current European Society of Cardiology guidelines recommend the use of hs-CTrop assays on admission and after 3 hours. Recent studies suggest that AMI can be diagnosed earlier than 3 hours, when values below the 99th percentile are used as cutoff values.

This study investigated the application of the CTrop-I assay for the diagnosis of AMI in 1,040 patients presenting to the emergency department with acute chest pain. Results were validated in 2 independent cohorts of 4,009 patients. The researchers found that with application of a new low hs-CTrop-I cutoff value of 6 ng/L, the rule-out algorithm showed a high negative predictive value of 99.8% after 1 hour for AMI, allowing for accurate and rapid exclusion of AMI. The l- and 3-hour approaches yielded results that were not statistically different. Similarly, a rule-in algorithm based on hs-CTrop-I levels provided a high positive predictive value with 83%. Application of the cutoff of 6 ng/L resulted in lower follow-up mortality (1%) compared with the routinely used 99th percentile (3.7%) for this assay.

“This cutoff [6 ng/L] enables a rapid triage that excludes AMI and a faster initiation of evidence-based treatment for patients diagnosed as having AMI,” the authors wrote.

The two studies, by Carlton E et al and by Neumann JT et al, were published online June 1, 2016, in the journal JAMA Cardiology.

Related Links:
North Bristol National Health Service Trust
University Hospital – Medical Center Hamburg-Eppendorf

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Immunofluorescence Analyzer
IFA System
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.